Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy

Journal of Cutaneous Pathology

Volumn 45, Issue 1, 2018, Pages 74-77

  Shao, Kimberly ^a   McGettigan, Suzanne ^a   Elenitsas, Rosalie ^a   Chu, Emily Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

drug reaction; lupus erythematosus; PD 1 inhibitor; pembrolizumab

Indexed keywords

IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ANTAGONISTS AND INHIBITORS; CASE REPORT; DRUG ERUPTION; HUMAN; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DRUG ERUPTIONS; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 85033564743     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.13059     Document Type: Article

References (27)

1. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. https://doi.org/10.1056/NEJMoa1412082.
2. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–1609. https://doi.org/10.1001/jama.2016.4059.
3. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158–176. https://doi.org/10.1111/cup.12858.
4. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117. https://doi.org/10.1016/S0140-6736(14)60958-2.
5. Hwang SJE, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455–461.e1. https://doi.org/10.1016/j.jaad.2015.10.029.
6. Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–1212. https://doi.org/10.1001/jamadermatol.2015.1916.
7. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381–384. https://doi.org/10.1111/cup.12876.
8. Nayar N, Briscoe K, Penas PF. Toxic epidermal necrolysis–like reaction with severe satellite cell necrosis associated with Nivolumab in a patient with Ipilimumab refractory metastatic melanoma. J Immunother. 2016;39(3):149–152. https://doi.org/10.1097/CJI.0000000000000112.
9. Mochel MC, Ming ME, Imadojemu S, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 2016;43:787–791. https://doi.org/10.1111/cup.12735.
10. Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis-type) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176:1649–1652. https://doi.org/10.1111/bjd.15237.
11. Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol. 2017;39(2):121–129. https://doi.org/10.1097/DAD.0000000000000688.
12. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339–346. https://doi.org/10.1111/cup.12666.
13. Abdel-Wahab N, Shah M, Suarez-Almazor ME, et al. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221. https://doi.org/10.1371/journal.pone.0160221.
14. Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following Ipilimumab therapy. JAMA Dermatol. 2015;151(2):195–199. https://doi.org/10.1001/jamadermatol.2014.2233.
15. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases – a general susceptibility gene to autoimmunity? Genes Immun. 2000;1(3):170–184. https://doi.org/10.1038/sj.gene.6363655.
16. Fadel F, El KK, Knebelmann B. Anti-CTLA4 antibody–induced lupus nephritis. N Engl J Med. 2009;361(2):211–212. https://doi.org/10.1056/NEJMc0904283.
17. Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57–75. https://doi.org/10.1517/17425255.2016.1120287.
18. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. https://doi.org/10.1016/j.ctrv.2016.02.001.
19. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092–2099. https://doi.org/10.1200/JCO.2014.60.0379.
20. FDA. Pembrolizumab Label.; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf.
21. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030. https://doi.org/10.1200/JCO.2013.53.0105.
22. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;67:JCO2017732289. https://doi.org/101200/JCO201773.2289.
23. Hwang SJE, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 2015;26:413–416. https://doi.org/10.1097/CMR.0000000000000260.
24. Weber JS, Dummer R, De Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–1682. https://doi.org/10.1002/cncr.27969.
25. Ahronowitz I, Fox L. Severe drug-induced dermatoses. Semin Cutan Med Surg. 2014;33(1):49–58.
26. Reinholz M, Berking C, Hermans C, Ruzicka T, Braun-Falco M. Lupus erythematosuselike skin eruption after vemurafenib therapy. J Am Acad Dermatol. 2014;71(4):e159–e160. https://doi.org/10.1016/j.jaad.2014.07.006.
27. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39(5):481–492. https://doi.org/10.1111/j.1600-0560.2012.01894.x.